JP2009509941A5 - - Google Patents

Download PDF

Info

Publication number
JP2009509941A5
JP2009509941A5 JP2008531412A JP2008531412A JP2009509941A5 JP 2009509941 A5 JP2009509941 A5 JP 2009509941A5 JP 2008531412 A JP2008531412 A JP 2008531412A JP 2008531412 A JP2008531412 A JP 2008531412A JP 2009509941 A5 JP2009509941 A5 JP 2009509941A5
Authority
JP
Japan
Prior art keywords
phe
aromatic
lys
arg
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008531412A
Other languages
English (en)
Japanese (ja)
Other versions
JP5416971B2 (ja
JP2009509941A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/036291 external-priority patent/WO2007035640A2/en
Publication of JP2009509941A publication Critical patent/JP2009509941A/ja
Publication of JP2009509941A5 publication Critical patent/JP2009509941A5/ja
Application granted granted Critical
Publication of JP5416971B2 publication Critical patent/JP5416971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008531412A 2005-09-16 2006-09-18 Ｃｄ３６の発現を減少させる方法 Active JP5416971B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71817005P 2005-09-16 2005-09-16
US60/718,170 2005-09-16
PCT/US2006/036291 WO2007035640A2 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012181082A Division JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Division JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法

Publications (3)

Publication Number Publication Date
JP2009509941A JP2009509941A (ja) 2009-03-12
JP2009509941A5 true JP2009509941A5 (enExample) 2009-10-01
JP5416971B2 JP5416971B2 (ja) 2014-02-12

Family

ID=37889419

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2008531412A Active JP5416971B2 (ja) 2005-09-16 2006-09-18 Ｃｄ３６の発現を減少させる方法
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Ｃｄ３６の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Ｃｄ３６の発現を減少させる方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Ｃｄ３６の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Ｃｄ３６の発現を減少させる方法

Country Status (10)

Country Link
US (10) US7541340B2 (enExample)
EP (5) EP3260127B1 (enExample)
JP (6) JP5416971B2 (enExample)
KR (9) KR20140042940A (enExample)
CN (6) CN104788540B (enExample)
AU (1) AU2006292352B2 (enExample)
CA (8) CA2622911C (enExample)
DK (1) DK1931369T3 (enExample)
HK (1) HK1206971A1 (enExample)
WO (1) WO2007035640A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
ES2694574T3 (es) 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7687243B1 (en) * 2005-06-06 2010-03-30 Crook Tonia M Automated method for detecting apoptosis in cells
AU2006292352B2 (en) * 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
EP2252312B1 (en) * 2008-02-07 2014-04-09 Cornell University Methods for preventing or treating insulin resistance
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
WO2011025734A1 (en) 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
US20110082084A1 (en) * 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US9283243B2 (en) * 2010-06-01 2016-03-15 Cornell University Cornell Center For Technology, Enterprise & Commercialization (“Cctec”) CD36 inhibition to control obesity and insulin sensitivity
CN106620645A (zh) 2010-07-09 2017-05-10 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
EP3281634A1 (en) * 2012-02-22 2018-02-14 Stealth Peptides International, Inc. Method and compositions for preventing or treating ophthalmic conditions
US9636378B2 (en) * 2012-03-30 2017-05-02 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment neuropathy
CA2880643A1 (en) 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
WO2014095875A1 (en) * 2012-12-18 2014-06-26 Per Olof Berggren Methods for treating and/or limiting development of diabetes
CA2912386A1 (en) * 2013-05-14 2014-11-20 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricular remodeling
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
US9895410B2 (en) * 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
WO2015095077A1 (en) * 2013-12-16 2015-06-25 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US11392555B2 (en) 2019-05-15 2022-07-19 Pure Storage, Inc. Cloud-based file services
WO2021021452A1 (en) * 2019-07-26 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University 1,8-cineol coated implants
CN115279394A (zh) 2019-11-20 2022-11-01 斯坦福大学托管董事会 用于放射治疗的预防性皮肤治疗
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ATE136905T1 (de) * 1988-06-30 1996-05-15 Astra Ab Dermorphin-analoge, deren herstellungsverfahren, pharmazeutische zusammensetzungen und methode zur therapeutischen behandlung unter verwendung der analoge
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
FR2756284B1 (fr) * 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU7856600A (en) * 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
ATE496533T1 (de) 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
DE10051983A1 (de) 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
OA12431A (en) * 2000-10-20 2006-04-19 Beate Kehrel Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
WO2002083106A1 (en) 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
AU2002360460A1 (en) * 2001-12-03 2003-06-17 Nuvelo, Inc. Methods and materials relating to novel polypeptides and polynucleotides
JP4346870B2 (ja) * 2002-07-05 2009-10-21 キッコーマン株式会社 血糖値上昇抑制用組成物
US7785567B2 (en) * 2002-08-23 2010-08-31 Valorisation-Recherche, Société en Commandite Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
ES2694574T3 (es) 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
US20050012597A1 (en) 2003-07-02 2005-01-20 Anderson Peter Traneus Wireless electromagnetic tracking system using a nonlinear passive transponder
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
CN1913774A (zh) 2003-12-12 2007-02-14 独立行政法人科学技术振兴机构 表达MEGSIN/RAGE/iNOS的疾病模型动物及借助于该动物评估化合物的方法
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US8157123B2 (en) * 2005-02-23 2012-04-17 The Glad Products Company Container
AU2006292352B2 (en) 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP2252312B1 (en) * 2008-02-07 2014-04-09 Cornell University Methods for preventing or treating insulin resistance
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
JP2012181082A (ja) * 2011-03-01 2012-09-20 Tokyo Electric Power Co Inc:The 仕切弁の分解点検補助装置およびその案内治具、並びに仕切弁の分解点検方法
CN202756379U (zh) 2012-07-13 2013-02-27 滨中元川金属制品（昆山）有限公司 一种自攻牙螺丝

Similar Documents

Publication Publication Date Title
JP2009509941A5 (enExample)
JP2012525844A5 (enExample)
Fernandez‐Yague et al. A self‐powered piezo‐bioelectric device regulates tendon repair‐associated signaling pathways through modulation of mechanosensitive ion channels
JP2022105138A5 (enExample)
JP2008508859A5 (enExample)
JP2006524034A5 (enExample)
Shifman et al. Expression of the netrin receptor UNC-5 in lamprey brain: modulation by spinal cord transection
JP2009501732A5 (enExample)
JP2011515407A5 (enExample)
EA023009B1 (ru) Ингибитор hcv сериновой протеазы, полученный из макроциклического пролина, и фармацевтическая композиция, предназначенная для лечения вирусной инфекции
JP2012507271A5 (enExample)
JP2013538560A5 (enExample)
CN1200127A (zh) 新的阿片样肽
JP2011513241A5 (enExample)
UA100222C2 (uk) Тканинозахисні пептиди і їх застосування
JP2006306885A5 (enExample)
JP2010533705A5 (enExample)
JP2005102701A5 (enExample)
JP2011526482A5 (enExample)
CN110381976A (zh) 包括肽wkdeagkplvk的组合物
JP2004531242A5 (enExample)
JP2006506942A5 (enExample)
JP2022531728A (ja) 胆汁酸塩ヒドロラーゼを使用して消化管を調節するための組成物及び方法
JP5749651B2 (ja) 多形核細胞の動員および／または遊走を減少させる化合物および方法
JP2004537284A5 (enExample)